s'authentifier
version française rss feed
Comparison of the pharmacokinetics of S-1, an oral anticancer agent, in Western and Japanese patients.
Comets E., Ikeda K., Hoff P., Fumoleau P., Wanders J., Tanigawara Y.
Journal of Pharmacokinetics and Pharmacodynamics 30, 4 (2003) 257-83 - http://www.hal.inserm.fr/inserm-00189555/en/
 (14650374) 
Comparison of the pharmacokinetics of S-1, an oral anticancer agent, in Western and Japanese patients.
Emmanuelle Comets () 1, 2, Kazumasa Ikeda3, Paulo Hoff4, Pierre Fumoleau5, Jantien Wanders6, Yusuke Tanigawara1
1 :  Department of Pharmacy
keio university hospital
Tokyo 160­-8582
Japon
2 :  Modèles et méthodes de l'évaluation thérapeutique des maladies chroniques
INSERM : E0357
GH Xavier Bichat, 48, Rue H. Huchart, 75018, Paris
France
3 :  Taiho Pharmaceutical Co, Ltd.
Taiho Pharmaceutical Co
Tokushima Research Center Tokushima 771-­0194
Japon
4 :  Department of Gastrointestinal Medical Oncology and Digestion Diseases
University of Texas
Department of Gastrointestinal Medical Oncology and Digestion Diseases University of Texas Houston
États-Unis
5 :  Centre René Gauducheau
http://www.centregauducheau.fr/
CRLCC René Gauducheau
Nantes
France
6 :  NDDO Oncology
NDDO Oncology
1081 JD Amsterdam
Pays-Bas
OBJECTIVE: S-1 is an oral anticancer agent combining tegafur (FT), a prodrug of 5-fluorouracil (5-FU), with potassium oxonate (oteracil) and gimeracil (CDHP) respectively to mitigate gastrointestinal toxicity and increase the half-life of 5-FU. This article presents a population pharmacokinetic analysis of these four compounds in Western cancer patients. The second objective was to compare the pharmacokinetics of S-1 in Western and Japanese patients. METHODS: A single dose (25-45 mg/m2) of S-1 was administered to 60 patients. In each patient, 6 concentrations of FT, 5-FU, oteracil and CDHP were measured over 24 hr. Using NONMEM, oteracil and CDHP were analyzed separately, and the individual estimates of CDHP parameters were included in the joint analysis of FT and 5-FU. We used validation techniques to assess differences between the two populations, and finally we compared the exposures in Western and Japanese patients using simulations. RESULTS: A compartmental model describing the PK of the 4 compounds was developed. The influence of CDHP on the elimination of 5-FU was well described by an enzymatic inhibition model. The model provided a good fit for all compounds. The pharmacokinetics for 5-FU and oteracil were similar between Western and Japanese patients, but apparent differences in exposure to 5-FU resulted from different total doses due to different body sizes.
Sciences du Vivant/Bio-Informatique, Biostatistique
Informatique/Bio-informatique
Anglais
1567-567X

Articles dans des revues avec comité de lecture
Journal of Pharmacokinetics and Pharmacodynamics (J Pharmacokinet Pharmacodyn)
Publisher Springer Verlag (Germany)
ISSN 1567-567X (eISSN : 1573-8744)
internationale
08/2003
30
4
257-83

5-FU – oral anticancer drug – population pharmacokinetics – model validation – ethnic differences
Administration – Oral – Adult – Aged – Antimetabolites – Antineoplastic – Asian Continental Ancestry Group – Chi-Square Distribution – Clinical Trials – Drug Combinations – Europe – Female – Humans – Male – Middle Aged – Models – Biological – Oxonic Acid – Pyridines – Statistics – Nonparametric – Tegafur – United States – Western World
During this work, Dr Emmanuelle Comets was supported by the fellowship program of the Japanese Society for the Promotion of Science
Liste des fichiers attachés à ce document : 
PDF
E671.pdf(815.6 KB)
XHTML
index.xhtml(86.3 KB)

tous les articles de la base du CCSd...